As of Oct 12, 2026 close
- Market cap
- $8.29B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $54.30$88.31
- Volume (live)
- -
- Avg. volume (3M)
- 2.13M
Cytokinetics, Incorporated (CYTK) Stock Price & Financial Analysis
Cytokinetics, Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $62.13 - $63.50 |
|---|---|
| 52-Week High | $88.31 |
| 52-Week Low | $54.30 |
| Open | $62.48 |
| Volume (last close) | 1.25M |
| Average Volume (3M) | 2.13M |
| Market Cap | 8.29B |
|---|---|
| Shares Outstanding | 132.09M |
| Price to Sales (P/S) | 122.56 |
| Price to Book (P/B) | -47.81 |
| EV/EBITDA | -11.45 |
| Revenue (TTM) | 67.67M |
|---|---|
| Net Income (TTM) | -894.00M |
| Free Cash Flow (TTM) | -580.71M |
| EPS (TTM) | $-7.18 |
| Profit Margin | -1321.12% |
| Operating Margin | -1046.12% |
| 50-Day MA | $71.55 |
|---|---|
| 200-Day MA | $70.14 |
| 1-Year Change | +5.37% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Cytokinetics, Incorporated at a Glance
Cytokinetics, Incorporated (CYTK) has a market capitalization of $8.29B. The stock trades at 122.6× sales. Over the trailing twelve months it lost $894.00M on revenue of $67.67M and burned $580.71M of free cash flow. Revenue fell 21.1% year over year.
It holds $255.27M in cash and securities against $1.15B of debt, a net debt position of $891.82M.
Cytokinetics, Incorporated does not currently pay a dividend.
The share price is up 5.4% over the past year. At $62.79 it sits within its 52-week range of $54.30 to $88.31, below its 200-day moving average of $70.14.
Based on 18 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $110.33, 75.7% above the latest close.
Frequently Asked Questions About Cytokinetics, Incorporated
What is the current stock price for CYTK?
As of the Oct 12, 2026 close, CYTK stock trades at $62.79. The 52-week range is $54.30–$88.31, with a day range of $62.13–$63.50.
What is the P/E ratio for CYTK?
The P/E ratio (Price-to-Earnings) for CYTK is shown in the Key Statistics section. This valuation metric helps compare Cytokinetics, Incorporated to industry peers.
Does CYTK pay dividends?
Cytokinetics, Incorporated does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for CYTK?
Based on 18 analysts, the consensus for CYTK is Buy.
What is the market cap of CYTK?
Cytokinetics, Incorporated's market capitalization is $8.29B, classifying it as a mid-cap company. Cytokinetics, Incorporated operates in the Healthcare sector within the Biotechnology industry.